arrow
M

Maureen M. O'Brien

university of colorado
H指数:43
被引数:6,539

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A real-world multi-institution experience of standard versus alternative dosing regimens of inotuzumab ozogamicin for relapsed/refractory paediatric B-cell acute lymphoblastic leukaemia

多机构真实世界经验:伊诺妥珠单抗标准剂量与替代剂量方案治疗复发/难治性儿童B细胞急性淋巴细胞白血病的比较

2026-10-220
PRE
A methotrexate dashboard: integrating MTXPK.org into the electronic health record to facilitate model-informed care for pediatric patients receiving high-dose methotrexate

甲氨蝶呤数据仪表盘:将MTXPK.org整合到电子健康记录中,以促进接受高剂量甲氨蝶呤治疗的儿科患者的模型化护理

2026-04-160
OA
A multicenter observational cohort study in survivors of Down Syndrome-associated acute leukemia (ALTE22C1): a report from the Children’s Oncology Group

一项多中心观察性队列研究,探讨唐氏综合征相关急性白血病的幸存者(ALTE22C1):美国儿童肿瘤学会的报告

2025-10-220
OAAI
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination

将患者报告结局纳入儿科癌症临床试验:设计、实施与传播

2025-03-310
PRE
Understanding the Associations between High-Dose Methotrexate Pharmacokinetics and the Risk of Adverse Events in Children and Adolescents with Down Syndrome Associated High-Risk Acute Lymphoblastic Leukemia

探讨唐氏综合征相关高危急性淋巴细胞白血病患者中,高剂量甲氨蝶呤药代动力学与不良事件风险之间的关联。

BLOOD
IF23.1
2024-11-050
PRE
A Children's Oncology Group Clinical Trial of Long-Term Outcomes in Survivors of Down Syndrome-Associated Acute Leukemia (ALTE22C1): Clinical Trial in Progress

儿童肿瘤组一项关于Down综合征相关急性白血病幸存者长期结局的临床试验(ALTE22C1):临床试验进行中

BLOOD
IF23.1
2024-11-050
PRE
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
2023-10-278
OAAI
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org
2023-08-031
OAAI
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL

选择常规化疗或Inotuzumab Ozogamicin作为过渡方案似乎不会影响小儿b-all对CD19-Directed car-t治疗的临床反应

2023-05-017
OAAI
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia

复发或难治性急性淋巴细胞白血病患儿接受inotuzumab ozogamicin治疗后嵌合抗原受体T细胞治疗的结果

LEUKEMIA
IF13.4
2022-10-309
PRE
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
2022-03-0436
OAAI
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (vol 33, pg 884, 2018)
LEUKEMIA
IF13.4
2019-03-074
OAAI
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

儿童复发/难治性急性淋巴细胞白血病患者的Inotuzumab ozogamicin

LEUKEMIA
IF13.4
2018-09-28147
OAAI